Open AccessCombination vinblastine, prednisolone and toceranib phosphate for treatment of grade II and III mast cell tumours in dogs
Author(s) -
Olsen Jaime A.,
Thomson Maurine,
O'Connell Kathleen,
Wyatt Ken
Publication year - 2018
Publication title -
veterinary medicine and science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.485
H-Index - 11
ISSN - 2053-1095
DOI - 10.1002/vms3.106
Subject(s) - medicine , vinblastine , prednisolone , chemotherapy , gastroenterology , neoadjuvant therapy , surgery , adjuvant therapy , adjuvant , retrospective cohort study , oncology , cancer , breast cancer
This retrospective study evaluates the progression‐free interval and survival outcomes of 40 canine ( Canis familiaris ) patients with Patnaik grade II and III mast cell tumours treated with combination vinblastine, prednisolone and toceranib phosphate from 2011 to 2015. Patients were subdivided into three groups; patients who received neoadjuvant therapy for poorly operable lesions, patients who received adjuvant therapy following surgical resection and patients being palliated for gross metastatic disease. Median survival time ( MST ) for the neoadjuvant group was not reached. Median survival time for the remaining groups was 893 days and 218 days, respectively. This combination demonstrated response in 90% (26/29) patients with measurable disease. The predominant side effects related to this chemotherapy combination were gastrointestinal in origin. Further prospective studies are required to further validate the efficacy of this treatment protocol.